Ruiqi Wang
Nankai University
9 Papers
11 Citations
Ruiqi Wang is an academic researcher from Nankai University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 2, co-authored 5 publications. Previous affiliations of Ruiqi Wang include Chinese PLA General Hospital.
Chat about Author
Papers
The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia
Caixia Han,Shujiao He,Ruiqi Wang,Xuefeng Gao,Hong Wang,Jingqiao Qiao,Xiangyu Meng,Yonghui Li,Li Yu +8 more
TL;DR: In this paper, the authors compared the transcriptional expression, prognosis, differentially expressed genes, functional enrichment, and hub genes in AML patients on the basis of the data published in the following databases: UALCAN, GEPIA, Gene Expression Omnibus, the Human Protein Atlas, Cancer Cell Line Encyclopedia, LinkedOmics, Metascape, and String.
Regulation of 3D Organization and Its Role in Cancer Biology
TL;DR: This review focuses on the relationships between tumor gene expression regulation, tumor 3D chromatin structure, and cancer phenotypic plasticity and looks forward to the clinical application prospects of 3D genomic biomarkers.
Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
TL;DR: In this article , the authors investigated the effects of NY-ESO-1-specific TCR-engineered T (TCR-T) cells combined with decitabine (DAC) against AML.
Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis
TL;DR: In this article, the authors conducted a meta-analysis to explore the effects of cytoreduction before transplantation for patients with myelodysplastic syndromes (MDS).
4
Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
TL;DR: In this article, the authors evaluated the characteristics and prognostic significance of gene mutations in refractory/relapsed (R/R) acute myeloid leukemia (AML) patients by comparing their gene mutation spectrum to those newly diagnosed.
2